Similar Median OS Between Ripretinib versus Sunitinib in Patients with Advanced GIST While Safety More Favourable for Ripretinib By Ogkologos - June 2, 2025 639 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the final overall survival and updated safety analysis of the INTRIGUE study Source RELATED ARTICLESMORE FROM AUTHOR No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe MOST POPULAR The team of over 60 scientists investigating the age-old mystery of... September 24, 2020 A Combination of Osimertinib Plus Pemetrexed and a Platinum-based Agent Significantly... November 29, 2023 FDA Approves Trastuzumab Deruxtecan for Any HER2-Positive Solid Cancer May 3, 2024 FDA Approves Encorafenib with Binimetinib for Metastatic Non-Small Cell Lung Cancer... October 16, 2023 Load more HOT NEWS Coffee Shop Owner Learns He Has Terminal Cancer – So Competitor... New Technology System Allows Patients To Get A Mammogram And Biopsy... Breast Cancer Survivor And Teenage Son Hand-Sew Neck Pillows To Bring... Immunotherapy’s Role in Treating Endometrial Cancer Expected to Grow
